Major Depressive Disorder (MDD) Clinical Trial
Official title:
A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder
Verified date | September 2021 |
Source | Otsuka Pharmaceutical Development & Commercialization, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This will be a multicenter, randomized, double-blind study designed to assess the efficacy, safety and tolerability of an oral Aripiprazole/Escitalopram combination therapy in participants with MDD who have demonstrated an incomplete response to a prospective trial of Escitalopram, and report a treatment history for the current MDD episode of an inadequate response to at least one and no more than three adequate trials of an approved antidepressant other than Escitalopram. An inadequate response is defined as less than a 50% reduction in depressive symptom severity as assessed by the participant's self-report on the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (ATRQ) and evaluated by the investigator as part of the participant's medical and psychiatric history. An adequate trial is defined as an antidepressant treatment for at least 6 weeks duration (or at least 3 weeks for combination treatments) at an approved dose as specified in the ATRQ.
Status | Terminated |
Enrollment | 237 |
Est. completion date | September 27, 2011 |
Est. primary completion date | September 27, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Participants with a current diagnosis of a major depressive episode. The current depressive episode must be = 8 weeks in duration - Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and during the study period - Participants with a 17-item Hamilton Depression Rating Scale (HAM-D17) total score = 18 at the Baseline Visit for the Prospective Treatment Phase. Exclusion Criteria: - Lack of prior treatment with an antidepressant during the current depressive episode - Participants who report treatment with adjunctive or monotherapy antipsychotic treatment during the current depressive episode. - Participants experiencing hallucinations, delusions or any psychotic symptomatology in the current depressive episode - Participants with epilepsy or significant history of seizure disorders - Participants with a clinically significant current diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal or histrionic personality disorder - Participants who have received electroconvulsive therapy (ECT) in the last 10 years. |
Country | Name | City | State |
---|---|---|---|
Romania | Study Site 1 | Bucuresti | |
Romania | Study Site 2 | Bucuresti |
Lead Sponsor | Collaborator |
---|---|
Otsuka Pharmaceutical Development & Commercialization, Inc. |
United States, Australia, Bulgaria, India, Philippines, Romania, Slovakia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase C: Mean Change From End of Phase B (Week 8) in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score to End of Phase C (Week 14) | The MADRS assessed severity of depressive symptoms. It ranges from a minimum of 0 to a maximum of 60 (higher scores indicating a greater severity of depressive symptoms). Participants are rated on 10 items (feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and a lack of interest) each on a 7-point scale from 0 (no symptoms) to 6 (symptoms of maximum severity). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses. | Week 8 to Week 14 | |
Secondary | Phase C: Clinical Global Impression - Improvement Scale (CGI-I) Score at The End of Phase C (Week 14) | The CGI-I is a 7-point scale that requires the clinician to assess how much the participant's illness has improved or worsened relative to a baseline state at the beginning of the intervention and rated as: 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse. Last observation carried forward (LOCF) method was used for analyses. | Week 14 | |
Secondary | Phase C: Mean Change From End of Phase B (Week 8) in the Sheehan Disability Scale (SDS) Mean Score to End of Phase C (Week 14) | The SDS is a 3-item clinician-rated questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0= no impairment to 10= most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe). A negative change from Week 8 indicates improvement. Last observation carried forward (LOCF) method was used for analyses. | Week 8 to Week 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00316160 -
Sexual Functioning Study With Antidepressants
|
Phase 4 | |
Completed |
NCT05416957 -
Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets
|
Phase 1 | |
Active, not recruiting |
NCT03642964 -
A Study in Patients With Major Depressive Disorder
|
Phase 2 | |
Terminated |
NCT01111565 -
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT01912196 -
Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)
|
Phase 2 | |
Completed |
NCT00958204 -
Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression
|
Phase 3 | |
Completed |
NCT00102492 -
Study Of GW679769 In Major Depressive Disorder
|
Phase 2 | |
Completed |
NCT02012218 -
Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy
|
Phase 3 | |
Completed |
NCT01477203 -
Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders
|
Phase 4 | |
Completed |
NCT00768430 -
Optimization of IV Ketamine for Treatment Resistant Depression
|
Phase 2 | |
Completed |
NCT00559299 -
Patient Tolerability Study of GSK163090
|
Phase 1 | |
Terminated |
NCT01123707 -
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
|
Phase 3 | |
Completed |
NCT04403373 -
Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study
|
N/A | |
Completed |
NCT05541302 -
Retrospective TMS Therapy for Adults With MDD
|
||
Recruiting |
NCT06385405 -
Electroencephalography-based Precise Repetitive Transcranial Magnetic Stimulation Treatment
|
N/A | |
Completed |
NCT00330616 -
Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan
|
Phase 2 | |
Recruiting |
NCT03012724 -
Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)
|
N/A | |
Completed |
NCT02380066 -
Comparison of Anyu Peibo With Placebo in Treatment of MDD
|
Phase 2 | |
Not yet recruiting |
NCT02395263 -
Comparison of Yuxintine With Placebo in Treatment of MDD
|
Phase 2 | |
Completed |
NCT01187407 -
A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
|
Phase 3 |